ERβ-targeted antagonists, such as tamoxifen, have been shown to significantly induce cell death in DLBCL and reduce the risk of DLBCL in patients with ERα+ breast cancer, highlighting the therapeutic potential of targeting ERβ in B-cell lymphoma treatment 142. This evidence concerns the gene ESR2 and B-cell non-Hodgkin lymphoma.